Korean skincare ingredient madecassic acid shows promise as a new antibiotic candidate by targeting bacterial respiration

Table of Contents

  1. Key Highlights:
  2. Introduction
  3. From beauty aisles to the bench: where madecassic acid comes from
  4. How madecassic acid disables bacteria: the cytochrome bd target
  5. How researchers combined computation and experiments to validate a natural product
  6. Why cytochrome bd presents a high-value target for new antibiotics
  7. Chemical tractability: why madecassic acid can be optimized
  8. Laboratory results: what the experiments showed
  9. Implications for skincare, the skin microbiome, and consumer products
  10. Challenges on the path from bench to bedside
  11. Natural products and modern discovery methods: a productive marriage
  12. Potential clinical niches and combination strategies
  13. What comes next: steps to move madecassic acid forward
  14. Broader strategies against antibiotic resistance: where this fits
  15. Real-world parallels that illustrate the path and pitfalls
  16. Ethical and regulatory considerations
  17. The practical significance for clinicians and consumers
  18. Closing perspective
  19. FAQ

Key Highlights:

  • Researchers at the University of Kent and UCL identified madecassic acid, a compound from Centella asiatica, as a potent inhibitor of the cytochrome bd respiratory complex in antibiotic-resistant E. coli.
  • Madecassic acid and three chemically modified variants suppressed bacterial growth in laboratory tests; one variant was bactericidal at higher concentrations, indicating clear potential for medicinal chemistry optimization.

Introduction

Antibiotic resistance now ranks among the most urgent public-health threats worldwide. Predictions suggest bacterial antimicrobial resistance could contribute to tens of millions of deaths over the coming decades, a stark indicator that the pace of new antibiotic discovery must accelerate. Scientists at the University of Kent, collaborating with University College London, have turned to a familiar botanical: Centella asiatica. Long prized in traditional medicine and modern skincare for its soothing properties, this plant contains madecassic acid — a small molecule that laboratory and computational evidence now identify as a direct inhibitor of a bacterial respiratory protein complex absent from humans. That selectivity positions madecassic acid as a rare natural product that could be transformed into a targeted antimicrobial, provided further optimization and rigorous testing.

The research, published in RSC Medicinal Chemistry, demonstrates how modern computational screening paired with classical microbiology can rapidly repurpose a natural compound into a focused lead for antibiotic development. The discovery highlights two converging trends: renewed interest in natural products as drug leads, and a strategic shift toward non-traditional bacterial targets, like respiratory proteins, that reduce collateral damage to host tissues. The findings also raise practical questions about how common cosmetic use of Centella-derived formulations might influence skin microbiomes. This article unpacks the science behind the discovery, explains why cytochrome bd is a compelling drug target, details the laboratory evidence, and outlines the obstacles and next steps needed to translate madecassic acid from a botanical extract to a bona fide antibiotic.

From beauty aisles to the bench: where madecassic acid comes from

Centella asiatica, often called gotu kola, is a low-growing perennial native to parts of Asia. Traditional systems of medicine have used the plant for wound healing, circulation, and cognitive benefits. In recent decades the extracts of Centella and isolated triterpenoid derivatives — asiaticoside, asiatic acid, and madecassic acid among them — became staples of cosmetic formulations. Skincare brands promote Centella extracts for calming inflammation, supporting barrier repair, and reducing redness. That commercial familiarity makes the molecule accessible to researchers and clinicians, but it also risks oversimplifying the compound’s biological potential.

Madecassic acid is a pentacyclic triterpenoid. Its structural skeleton gives it enough complexity to interact with protein surfaces, while retaining functional groups amenable to chemical modification. The University of Kent team isolated madecassic acid from a plant extract sourced in Vietnam. Isolation from botanical material remains a common first step: botanicals often contain small quantities of bioactive compounds that can then be purified, structurally characterized, and used as templates for analogue synthesis. The Kent researchers then took the compound beyond cosmetic claims, testing its effects against antibiotic-resistant Escherichia coli strains and probing the molecular basis for its activity.

This transition from topical comfort ingredient to antimicrobial lead underscores the dual nature of many natural products. A single molecule can serve distinct roles depending on formulation, dose, and route of administration. Skincare formulations deliver low concentrations that are intended to modulate inflammation or barrier function on the surface of the skin. An antibiotic requires sufficient systemic or local concentration to reach and disable a pathogen — and it must do so while avoiding harm to human cells. Early-stage laboratory work answers the critical first question: does the compound exert a direct and specific effect on bacteria that can be optimized?

How madecassic acid disables bacteria: the cytochrome bd target

Bacteria rely on respiratory complexes to generate energy, particularly under the low-oxygen or fluctuating-oxygen conditions encountered during infections. Cytochrome bd is a membrane-associated terminal oxidase found in many pathogenic bacteria, including E. coli. It plays a central role in bacterial respiration under oxygen-limited environments and contributes to survival within host tissues. Crucially, cytochrome bd does not exist in humans or other animals; animals rely on cytochrome c oxidase (complex IV) rather than the bacterial bd oxidase. That absence offers a therapeutic window: a drug that inhibits cytochrome bd can cripple bacterial energy metabolism without directly targeting homologous human proteins.

The Kent–UCL team combined computational docking and laboratory assays to show that madecassic acid binds strongly to the cytochrome bd complex and inhibits its function. When bound, the molecule appears to prevent the complex from carrying out its role in the electron transport chain, impairing bacterial respiration and blocking growth. In practical terms, cytochrome bd inhibition deprives bacteria of a key energy pathway used during infection, pushing them toward energy collapse or rendering them more vulnerable to the immune system and to partner antibiotics.

Targeting respiratory machinery has strategic advantages. Respiratory complexes are essential under the stressful conditions bacteria face during colonization and infection — low oxygen, reactive oxygen species, and nutrient limitation. Drugs that attack processes essential in those contexts can achieve therapeutic effects at concentrations that would not be relevant in purely laboratory growth conditions. Furthermore, because cytochrome bd is structurally distinct from human respiratory proteins, inhibitors can be selective and potentially display favorable safety profiles.

How researchers combined computation and experiments to validate a natural product

The study used a two-pronged approach. Computational screening — often called in silico docking — predicts how small molecules might bind to target proteins. Researchers can model the three-dimensional structure of a bacterial protein, map potential binding pockets, and calculate which compounds may bind with high affinity. Computational methods narrow the universe of candidates and suggest testable hypotheses about binding modes and key interactions.

Kent’s team used computational screening to propose that madecassic acid would dock into cytochrome bd and form stable interactions. Those predictions guided wet-lab experiments. The researchers isolated madecassic acid from Centella extract, synthesized three chemical variants designed to probe and enhance activity, and tested the compounds in a series of assays:

  • Biochemical assays to measure direct inhibition of cytochrome bd function.
  • Bacterial growth assays using antibiotic-resistant E. coli strains to determine whether inhibition translated into reduced proliferation.
  • Dose-response experiments to determine the concentrations at which growth was arrested and, in some cases, whether bacteria were killed outright.

Every modified variant retained the ability to inhibit cytochrome bd and suppress E. coli growth. One variant demonstrated bactericidal activity at higher concentrations, killing E. coli rather than merely inhibiting growth. Together, the computational and experimental data form a coherent picture: madecassic acid binds and disables a bacterial respiratory complex, and chemical modifications can increase potency.

This workflow — from computational hypothesis to experimental validation — exemplifies contemporary natural-product research. Historically, natural products provided leads that then required laborious activity-guided fractionation and serendipity. Today, in silico techniques speed target identification and enable rational modification, focusing scarce laboratory resources on the most promising derivatives.

Why cytochrome bd presents a high-value target for new antibiotics

Antibiotic discovery increasingly prioritizes targets that are essential for bacterial survival in host-relevant conditions and absent from humans. Cytochrome bd satisfies both criteria. The enzyme is particularly important during infection because it helps bacteria cope with oxygen-limited niches and resist oxidative stress produced by host immune cells. Pathogens that upregulate cytochrome bd during infection may become dependent on it for survival, making the oxidase a vulnerability.

Selectivity matters. Human cells do not express cytochrome bd, so drugs that target it are less likely to interfere with human mitochondrial respiration. The risk of off-target toxicity often limits antibiotics that act on conserved processes shared with eukaryotes; cytochrome bd avoids that restriction. In addition, cytochrome bd has structural and regulatory roles tied to biofilm formation, persister cell physiology, and survival under antibiotic pressure. Inhibitors of bd oxidase could therefore not only reduce viable bacterial counts but also sensitize bacteria to existing antibiotics, offering combination therapy opportunities.

From a resistance-management perspective, targeting energy metabolism alters the selective landscape. Classic antibiotics commonly target cell-wall synthesis, protein synthesis, DNA replication, or folate metabolism. Bacteria have evolved or acquired resistance mechanisms against many of these classes. Respiratory inhibitors introduce a different pressure point. Combining such inhibitors with traditional drugs could reduce the probability of resistance emergence, especially if the inhibitors cripple bacterial stress responses needed to survive antibiotic assault.

Chemical tractability: why madecassic acid can be optimized

A lead compound’s success depends as much on chemistry as on biology. Madecassic acid is a small molecule with a defined scaffold that allows medicinal chemists to tune potency, selectivity, pharmacokinetics, and safety. The Kent team capitalized on that amenability, synthesizing three variants that preserved the triterpenoid core while altering peripheral functional groups. All derivatives retained activity against cytochrome bd and bacterial growth; one reached concentrations that killed E. coli outright.

Optimization follows several parallel paths. Medicinal chemists aim to increase binding affinity and improve on-target potency while reducing off-target interactions that cause toxicity. Structural activity relationships (SAR) guide modifications: changing polarity to improve membrane permeation into Gram-negative bacteria, altering molecular weight to favor penetration of bacterial outer membranes, or adding moieties that reduce metabolic breakdown in vivo. For compounds that target membrane-associated proteins like cytochrome bd, lipophilicity and amphipathic character become crucial to reach and embed in bacterial membranes.

Beyond potency, drug-like properties must be addressed. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) determine whether a potent laboratory compound can become a safe systemic medicine. Some natural products fail because they are rapidly metabolized, poorly soluble, or exhibit toxic liabilities at therapeutic doses. The advantage of madecassic acid lies in its modifiable backbone. Early variants that demonstrate varying degrees of activity offer data points for SAR modeling and further rounds of optimization.

Medicinal chemistry will also consider formulation strategies. For systemic infections, oral bioavailability is often desirable but difficult for complex natural products. Intravenous administration can bypass some barriers but introduces formulation and safety hurdles. For skin infections or topical prophylaxis, local delivery through creams or gels can exploit Centella’s historical use while delivering higher local concentrations with limited systemic exposure.

Laboratory results: what the experiments showed

The Kent–UCL collaboration reported several experimental outcomes that support madecassic acid as a lead antibacterial:

  • Direct binding: Computational docking predicted high-affinity interactions with cytochrome bd, and experimental assays corroborated inhibition of the complex’s activity.
  • Growth inhibition: Madecassic acid and its three synthesized variants effectively stopped growth of antibiotic-resistant E. coli strains in vitro.
  • Bactericidal activity: One variant achieved bactericidal concentrations, demonstrating that chemical modification can increase lethality and not only stasis.
  • Selectivity potential: Because cytochrome bd does not exist in mammalian cells, the mechanism of action suggests a pathway to selectivity that reduces the likelihood of mitochondrial toxicity.

These outcomes provide a credible starting point for lead optimization. They also underscore the need for follow-on studies: testing across a broader panel of clinically relevant pathogens, assessing activity in the presence of body fluids and host cells, and moving toward animal infection models to evaluate efficacy and safety in a living system.

Implications for skincare, the skin microbiome, and consumer products

Centella asiatica extracts appear in many topical products at low concentrations for their anti-inflammatory and barrier-supporting properties. The discovery that madecassic acid can inhibit bacterial respiration raises practical questions about long-term cosmetic use and its effects on skin flora.

Skin microbiomes are complex ecosystems. Many communities of bacteria provide protective functions, antagonize pathogens, and contribute to cutaneous immunity. Broad-spectrum antimicrobial activity in a cosmetic product can disrupt beneficial flora and potentially select for resistant strains if exposure is frequent and subinhibitory. However, topical formulations typically use low concentrations, and many skincare ingredients exert modulatory rather than bactericidal effects.

If madecassic acid or derivatives were advanced toward topical clinical indications — for example, treating drug-resistant wound infections or localized cutaneous pathogens — formulation modifications would likely deliver higher local concentrations than found in cosmetics. Those elevated exposures would require formal safety evaluation and microbiome impact studies.

Two pragmatic paths emerge. First, regulators and manufacturers could reassess cosmetic concentration limits and labeling if data indicate significant antimicrobial activity at consumer-use levels. Second, the molecule might be repurposed into regulated topical therapeutics with defined dosing, safety testing, and targeted indications, distinct from over-the-counter cosmetic claims. Either path demands evidence: controlled studies that measure the compound’s effects on resident skin bacteria, its potential to select for resistant organisms, and any interaction with human skin cells.

Challenges on the path from bench to bedside

Translating a promising laboratory lead into an approved antibiotic remains an arduous process. Several major hurdles stand between madecassic acid’s current status and a licensed drug:

  1. Efficacy in animal models: In vitro inhibition does not guarantee in vivo efficacy. Animal infection models test whether the compound reaches the site of infection, maintains activity in the host environment, and reduces pathogen burden without undue toxicity.
  2. Pharmacokinetics and formulation: Achieving effective and safe concentrations in target tissues requires appropriate absorption and distribution. For bloodstream or deep-tissue infections, systemic exposure is necessary. For topical or inhaled routes, localized delivery may suffice but still requires formulation science to stabilize the molecule and ensure penetration.
  3. Safety and toxicity: Preclinical toxicity studies evaluate acute and chronic effects on host organs, potential mutagenicity, effects on mitochondrial function, and any immunological consequences. Even with a selective bacterial target, metabolites or high concentrations can produce unforeseen toxicity.
  4. Resistance emergence: Bacteria may mutate target proteins or upregulate compensatory pathways. Long-term studies must assess the propensity for resistance development and whether the compound synergizes with existing therapies to limit selection pressure.
  5. Regulatory and commercial hurdles: Clinical trials are expensive, lengthy, and subject to strict regulatory oversight. Because antibiotics often generate lower returns on investment relative to chronic therapies, funding and commercial strategies must be aligned with public-health incentives and potential partnership models.
  6. Gram-negative permeability: Many antibiotics fail against Gram-negative pathogens because of the outer membrane barrier and active efflux pumps. E. coli is Gram-negative, so the ability of madecassic acid and its variants to traverse or disrupt outer membranes is critical. Medicinal chemistry must address uptake and retention in Gram-negative bacteria.

Addressing these challenges requires coordinated teams of chemists, microbiologists, pharmacologists, and clinicians, plus funding that recognizes antibiotics’ societally valuable but commercially constrained nature.

Natural products and modern discovery methods: a productive marriage

Natural products have been central to pharmacology since penicillin emerged from Penicillium molds and streptomycin from soil actinomycetes. Artemisinin, an antimalarial derived from Artemisia annua, offers a modern example of a plant compound transformed into essential global medicine. These successes came from empirical observation followed by intense optimization.

The madecassic acid story illustrates a modern twist: computational tools accelerate target identification and rational modifications. In silico docking can suggest molecular interactions that are then validated in biochemical and microbiological assays. That feedback loop shortens the path from botanical hit to a medicinal chemistry program.

Other plant-derived antimicrobials have shown promise but also illustrate pitfalls. Compounds like berberine exhibit antimicrobial properties but suffer from poor bioavailability and toxicity at higher doses. Essential oils such as tea tree oil have topical antimicrobial effects but lack the specificity and pharmacology required for systemic therapy. The difference between these examples and madecassic acid lies in target specificity and chemical modifiability. When a natural product binds a well-defined bacterial protein absent in humans, medicinal chemistry can sculpt potency while preserving safety.

Applying modern high-throughput screening, structure-based design, and fragment-based approaches to natural product scaffolds broadens the repertoire of druggable chemical space. Rather than discarding complex natural molecules as intractable, researchers now view them as sophisticated starting points for drug discovery.

Potential clinical niches and combination strategies

If further development confirms safety and efficacy, madecassic acid derivatives could fill several clinical roles:

  • Adjunctive therapy: Combining a cytochrome bd inhibitor with conventional antibiotics may potentiate activity, especially against strains that rely on respiratory flexibility to survive antibiotic stress. For example, pairing with cell-wall antibiotics could amplify lethality in oxygen-limited infection niches.
  • Topical antimicrobials: For wound infections, diabetic ulcers, or localized skin infections with antibiotic-resistant organisms, a topically applied cytochrome bd inhibitor could deliver high local concentrations with minimal systemic exposure.
  • Narrow-spectrum therapeutics: Selective targeting of pathogens that depend on cytochrome bd during certain infections might reduce microbiome disruption compared with broad-spectrum agents.

Combination strategies deserve particular attention. Inhibitors of bacterial respiration can sensitize persisters and biofilm-embedded cells — bacterial phenotypes notoriously tolerant to many antibiotics. Carefully designed regimens pairing respiratory inhibitors with conventional agents may shorten treatment durations and reduce relapse rates. Clinical validation will require rigorous synergy testing and thoughtful trial design.

What comes next: steps to move madecassic acid forward

Advancing madecassic acid will follow a typical preclinical and translational sequence, fleshed out here with specific scientific goals:

  1. Broader spectrum testing: Evaluate activity against a panel of clinically relevant pathogens (other Enterobacterales, Pseudomonas aeruginosa, Klebsiella spp., Staphylococcus aureus where relevant) and across resistant phenotypes.
  2. Mechanistic depth: Use structural biology (X-ray crystallography, cryo-EM) to determine the binding mode of madecassic acid and its variants to cytochrome bd. High-resolution structures inform precise medicinal chemistry.
  3. Medicinal chemistry optimization: Iterative synthesis guided by SAR and ADMET profiling to enhance potency, permeability (particularly across Gram-negative outer membranes), metabolic stability, and solubility.
  4. In vivo efficacy: Test lead candidates in animal infection models that mimic clinically relevant states — bloodstream infections, urinary-tract infections, wound models — to assess therapeutic windows and dosing strategies.
  5. Safety assessment: Conduct preclinical toxicology studies, including genotoxicity, cardiotoxicity (hERG channel assays), mitochondrial function assays, and systemic organ toxicity in rodents and non-rodents.
  6. Formulation development: Create stable formulations appropriate to intended use — topical gels, intravenous solutions, or oral formulations — and confirm bioavailability and pharmacodynamics.
  7. Resistance surveillance: Monitor for resistance emergence in vitro and in serial-passage experiments to design stewardship strategies and identify combination partners that suppress resistance.
  8. Clinical development plan: If preclinical data are favorable, file for regulatory approvals required to begin Phase I human trials focusing on safety and pharmacokinetics, followed by Phase II efficacy trials in defined patient populations.

Each step is resource-intensive. Public-private partnerships, government incentives for antibiotic development, and philanthropic funding often underpin programs that address high-priority resistant pathogens.

Broader strategies against antibiotic resistance: where this fits

Madecassic acid is one piece of a larger puzzle. Addressing antimicrobial resistance requires multiple convergent strategies:

  • Stewardship: Prudent antibiotic prescribing and agricultural antibiotic reduction slow the spread of resistance.
  • Rapid diagnostics: Faster identification of pathogens and their susceptibilities enables targeted therapy, reducing unnecessary broad-spectrum use.
  • Alternative therapies: Bacteriophages, monoclonal antibodies, and antimicrobial peptides expand therapeutic options beyond small molecules.
  • Vaccination: Preventing bacterial infections reduces antibiotic demand.
  • Drug discovery innovation: New targets like cytochrome bd diversify the mechanistic portfolio and reduce selective pressure on any single pathway.

Within this ecosystem, madecassic acid derivatives would act as targeted tools, particularly valuable when traditional classes fail. The discovery highlights how natural products, when combined with modern techniques, remain indispensable in expanding the antibiotic armamentarium.

Real-world parallels that illustrate the path and pitfalls

History offers instructive parallels. Penicillin’s discovery transformed medicine but required decades of optimization for stable production and clinical deployment. Artemisinin’s successful path from plant extract to global antimalarial involved meticulous chemical modification and clinical validation, culminating in lifesaving therapies. Both stories emphasize patient-focused development, rigorous clinical data, and supply-chain solutions.

Other natural products show limitations. Berberine has antibacterial activity in vitro but poor oral bioavailability and potential drug interactions limit systemic use. Tea tree oil illustrates how topical antimicrobials can be widely used without meeting drug regulatory standards, sometimes fostering variable quality and concerns about sensitization. These contrasts stress that madecassic acid’s promise depends on rigorous chemical and clinical development, not mere botanical presence in consumer goods.

Ethical and regulatory considerations

Developing plant-derived antibiotics raises ethical and regulatory questions. Bioprospecting must respect source-country sovereignty and local knowledge, ensuring benefit-sharing with communities that stewarded the botanical resources. Intellectual property strategies must balance commercial incentives with equitable access, particularly when addressing global health threats.

Regulatory frameworks for antibiotics prioritize safety, efficacy, and stewardship. For topical products derived from botanical extracts, cosmetics regulations differ from drug approval pathways, which may create grey zones. If a product claims to treat or prevent infections, it will fall under medicinal product regulations and require clinical data. Transparency about concentrations, indications, and evidence is essential to protect consumers and public-health interests.

The practical significance for clinicians and consumers

For clinicians, the discovery signals an emerging class of targeted agents that could complement existing therapies. A cytochrome bd inhibitor that proves effective in vivo would offer a strategic tool against infections where respiratory flexibility underpins persistence and resistance.

Consumers should not equate Centella-containing cosmetics with antibiotics. Cosmetic concentrations and formulations are not designed to treat infection. However, manufacturers and regulators should monitor evidence about antimicrobial activity in cosmetic ingredients to prevent unintended microbiome disruption or misleading claims.

Clinicians and dermatologists should remain alert to evidence as it emerges. If madecassic acid derivatives progress into topical therapeutics, they will require distinct prescribing guidance, resistance monitoring, and integration into stewardship programs.

Closing perspective

Antibiotic discovery benefits from both ancient knowledge and modern science. Madecassic acid exemplifies how a molecule with a long history of topical use can reveal unexpected therapeutic potential when subjected to contemporary target-focused screening and chemical modification. The findings from the University of Kent and UCL do not produce an immediately deployable drug, but they identify a tangible lead: a plant-derived inhibitor of a bacterial respiratory complex absent from humans. That lead opens a rational path for medicinal chemistry and preclinical development.

Progress will hinge on demonstrating efficacy in relevant infection models, optimizing pharmacology, and addressing safety and resistance risks. If those hurdles are overcome, madecassic acid derivatives could join a short list of new antibiotics that target previously underexploited bacterial processes, expanding the toolkit available to clinicians confronting resistant infections.

FAQ

Q: What exactly is madecassic acid? A: Madecassic acid is a pentacyclic triterpenoid natural product found in Centella asiatica. It has been used traditionally and appears in modern skincare products for its anti-inflammatory and wound-healing properties.

Q: How does madecassic acid kill or inhibit bacteria? A: Laboratory evidence indicates madecassic acid binds to and disables the bacterial cytochrome bd respiratory complex, which impairs energy generation under the low-oxygen, stress-rich conditions bacteria face during infection. Inhibition of this complex shuts down respiration and halts bacterial growth; certain modified variants can be bactericidal at higher concentrations.

Q: Why is cytochrome bd a good antibiotic target? A: Cytochrome bd is absent in humans and animals, reducing the risk of directly damaging host respiratory proteins. It is essential for bacterial survival under infection-relevant conditions, making it a vulnerability. Targeting bd may also sensitize bacteria to other antibiotics and limit mechanisms of resistance tied to more commonly targeted pathways.

Q: Does this mean Centella-containing skincare products are antibiotics? A: Not necessarily. Cosmetic products generally contain low concentrations of botanical extracts for skin-conditioning effects. While madecassic acid has antimicrobial activity in laboratory settings, consumer products use much lower doses and formulations that prioritize safety and tolerability. Any claim that a cosmetic product functions as an antibiotic would require regulatory approval and clinical evidence.

Q: How far is this research from producing a usable antibiotic? A: Early-stage but promising. The work demonstrates target engagement and in vitro efficacy. Translating that into a medicine requires medicinal chemistry optimization, ADMET profiling, animal efficacy and toxicity studies, and ultimately human clinical trials. That pipeline typically spans years and requires significant resources.

Q: Could bacteria quickly develop resistance to cytochrome bd inhibitors? A: Resistance can emerge to any antibiotic. The advantage of cytochrome bd inhibitors lies in targeting a process essential during infection and absent in humans. Combining bd inhibitors with other antibiotics may reduce resistance emergence. Nevertheless, careful surveillance and resistance-proofing strategies will be essential during development.

Q: Are there safety concerns because the compound affects respiration? A: Human respiration relies on different proteins (cytochrome c oxidase), so a compound that selectively targets bacterial cytochrome bd should avoid direct mitochondrial toxicity. Safety concerns remain, however: metabolites, off-target effects, and high-dose exposures can produce toxicities. Preclinical safety studies will examine these risks thoroughly.

Q: Could madecassic acid be used topically to treat skin infections? A: Topical use is a plausible and potentially shorter route to clinic. Delivering high local concentrations to infected skin or wounds could limit systemic exposure. Topical development still requires controlled efficacy and safety trials, formulation work, and microbiome impact assessments.

Q: How does this discovery fit into broader antibiotic development efforts? A: It exemplifies a broader shift: re-examining natural products with modern computational and structural tools to find selective bacterial targets beyond classic mechanisms. This approach complements other strategies — stewardship, diagnostics, alternative therapeutics — that together tackle antibiotic resistance.